Metastatic Colorectal Cancer (mCRC) Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | Pfizer, Sanofi, Taiho Pharma, Ono Pharma, Isofol, Merck, AB Science, Daiichi Sankyo, Astrazeneca, Eisai, Menarini, Immunovative

As per DelveInsight, the Metastatic Colorectal Cancer Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Metastatic Colorectal Cancer and the launch of new therapies in the market.

DelveInsight's "Metastatic Colorectal Cancer (mCRC) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Metastatic Colorectal Cancer Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Metastatic Colorectal Cancer therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Metastatic Colorectal Cancer treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Metastatic Colorectal Cancer (mCRC): An Overview
Colorectal cancer (CRC) is the third most common type of cancer, with metastasis being the major cause of death in the majority of patients. CRC that spreads, or metastasizes, to the lungs, liver or any other organ is called metastatic colorectal cancer (mCRC).

Generally, most CRCs (95%) are considered sporadic, meaning the genetic changes develop by chance after a person is born, so there is no risk of passing these genetic changes on to one's children. Inherited CRCs are less common (5%) and occur when gene mutations, or changes, are passed within a family from one generation to the next. Often, the cause of CRC is not known.

The symptoms of mCRC depend on where the cancer has spread and the size of the metastatic tumor. Some of the symptoms are-jaundice or abdominal swelling (when cancer has spread to the liver), shortness of breath (when cancer has spread to the lung), bone pain and fractures (when cancer has spread to the bone), and dizziness, headache, or seizures (when cancer has spread to the brain). After someone is diagnosed with CRC, staging is done to figure out if it has spread, and if so, how far. CRC can be divided into localized, regional, distant, and unknown based on CRC staging.

Metastatic Colorectal Cancer (mCRC) Market Key Facts
• In 2021, the Metastatic Colorectal Cancer market size was USD 12,613.9 million, which is expected to rise during the study period (2019-2032).
• The Metastatic Colorectal Cancer market size in the United States accounted for USD 5,155.1 million in 2021.
• In the year 2021, the total incident cases of Metastatic Colorectal Cancer were 241,100+ cases in the 7MM which is expected to grow during the study period, i.e., 2019-2032.
• In the EU-5 countries, the incident cases of metastatic colorectal cancer were around 108,000+ cases in the year 2021, with the highest cases being reported in Germany.

Discover How the Metastatic Colorectal Cancer Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Metastatic Colorectal Cancer (mCRC) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Metastatic Colorectal Cancer therapies in the market. It also provides a detailed assessment of the Metastatic Colorectal Cancer market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Metastatic Colorectal Cancer drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Metastatic Colorectal Cancer (mCRC) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Metastatic Colorectal Cancer patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Metastatic Colorectal Cancer Epidemiology Segmented as -
• Incident Cases of Colorectal Cancer (CRC) in the 7MM [2019-2032]
• Incident Cases of Metastatic Colorectal Cancer (mCRC) in the 7MM [2019-2032]

Get Key Insights Into the Evolving Metastatic Colorectal Cancer Epidemiology Trends @
https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Metastatic Colorectal Cancer (mCRC) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Colorectal Cancer market or expected to be launched during the study period. The analysis covers the market share by Metastatic Colorectal Cancer drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Metastatic Colorectal Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Metastatic Colorectal Cancer Market @
https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Metastatic Colorectal Cancer Therapeutics Assessment
Currently, the first, second, and third-line treatment regimen of mCRC involves the use of multiagent
chemotherapy (i.e. FOLFOX, FOLFIRI, CAPEOX), anti-angiogenesis therapy with or without chemotherapy, Epidermal growth factor receptor (EGFR) inhibitors with or without chemotherapy, Keytruda, Opdivo with or without Yervoy, Braftovi in combination with Erbitux and others with chemotherapy.

Several major pharma and biotech companies are actively engaged in the development of therapies for metastatic colorectal cancer. Among these companies, those with drug candidates in the most advanced stage of clinical development, specifically in phase III trials, include Mirati Therapeutics.

The market space of mCRC would benefit in the coming years with the launch of several emerging therapies. These therapies include triplet combination of Braftovi + Mektovi + Erbitux, Modufolin (arfolitixorin) + bevacizumab, Adagrasib, Lumakras (sotorasib) + panitumumab, Elunate (fruquintinib), Tukysa (tucatinib) ± Herceptin (trastuzumab), Onvansertib.

Leading Companies in the Metastatic Colorectal Cancer Therapeutics Market Include
The pharmaceutical and biotechnology landscape features several prominent companies making significant contributions to the Metastatic Colorectal Cancer Therapeutics field. Some of these key players include Pfizer, Sanofi, Taiho Pharma, Ono Pharma, Hutchison Medipharma, Isofol Medical, Sumitomo Dainippon Pharma, G1 Therapeutics, Merck, AB Science, Daiichi Sankyo/Astrazeneca, Merck/Eisai, Mirati Therapeutics, Cardiff Oncology, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, TreosBio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, and Shanghai Henlius Biotech. These companies collectively represent a diverse range of expertise and innovation in the pharmaceutical and biotech sectors.

Emerging and Marketed Metastatic Colorectal Cancer Therapies Covered in the Report Include
• Adagrasib (MRTX849) + cetuximab: Mirati Therapeutics + Merck
• MK-4280A (favezelimab and pembrolizumab): Merck
• Elunate (fruquintinib/HMPL-013): Hutchison Medipharma
• Corsela (trilaciclib): G1 Therapeutics
• Modufolin (arfolitixorin): Isofol Medical
• Keytruda (pembrolizumab) injection: Merck
• Stivarga (Regorafenib): Alexion Pharmaceuticals
• Jemperli (dostarlimab): GlaxoSmithKline (GSK)
• Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib): Array BioPharma/ Pfizer + Pfizer
And Many Others

Learn More About the Emerging Therapies and key Companies in the Metastatic Colorectal Cancer Therapeutics Market @
https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Metastatic Colorectal Cancer Competitive Intelligence Analysis
4. Metastatic Colorectal Cancer Market Overview at a Glance
5. Metastatic Colorectal Cancer Background and Overview
6. Metastatic Colorectal Cancer Patient Journey
7. Metastatic Colorectal Cancer Epidemiology and Patient Population
8. Metastatic Colorectal Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Metastatic Colorectal Cancer Unmet Needs
10. Key Endpoints of Metastatic Colorectal Cancer Treatment
11. Metastatic Colorectal Cancer Marketed Products
12. Metastatic Colorectal Cancer Emerging Therapies
13. Metastatic Colorectal Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Metastatic Colorectal Cancer Market Outlook (7 major markets)
16. Metastatic Colorectal Cancer Access and Reimbursement Overview
17. KOL Views on the Metastatic Colorectal Cancer Market.
18. Metastatic Colorectal Cancer Market Drivers
19. Metastatic Colorectal Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.